{'fraction_non_alphanumeric': 0.028208744710860368, 'fraction_numerical': 0.015514809590973202, 'mean_word_length': 5.513761467889908, 'pattern_counts': {'":': 1, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Commentary on the American College of Rheumatology "COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases": use of tofacitinib in the context of COVID-19 vaccination.

We read with great interest the ACR's COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases (1). We commend the Task Force's emphasis on the importance of immunization in this population and for providing guidance to the rheumatology community. Regarding their recommendation to hold Janus kinase (JAK) inhibitors for 1 week after each COVID-19 vaccine dose (1), we propose the following available tofacitinib data for consideration in this context.